1. Home
  2. SOHU vs AGEN Comparison

SOHU vs AGEN Comparison

Compare SOHU & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

N/A

Current Price

$13.62

Market Cap

337.1M

Sector

Technology

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$6.94

Market Cap

274.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SOHU
AGEN
Founded
1996
1994
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
337.1M
274.8M
IPO Year
2018
1999

Fundamental Metrics

Financial Performance
Metric
SOHU
AGEN
Price
$13.62
$6.94
Analyst Decision
Strong Buy
Buy
Analyst Count
2
2
Target Price
$20.00
$14.50
AVG Volume (30 Days)
58.0K
996.7K
Earning Date
05-18-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
N/A
0.96
Revenue
N/A
$42,877,086.00
Revenue This Year
$1.61
$107.63
Revenue Next Year
$3.78
N/A
P/E Ratio
$1.16
$7.15
Revenue Growth
N/A
89.95
52 Week Low
$11.61
$2.71
52 Week High
$17.30
$8.85

Technical Indicators

Market Signals
Indicator
SOHU
AGEN
Relative Strength Index (RSI) 40.20 44.89
Support Level $13.38 $2.97
Resistance Level $13.61 $8.70
Average True Range (ATR) 0.50 0.53
MACD -0.12 -0.21
Stochastic Oscillator 19.34 12.37

Price Performance

Historical Comparison
SOHU
AGEN

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: